Fasting group | Fed group | |||
---|---|---|---|---|
T | R | T | R | |
Ezetimibe | ||||
Cmax (ng/mL) | 3.23 ± 1.41 | 3.48 ± 1.82 | 5.94 ± 4.12 | 5.81 ± 3.06 |
AUC0–t (ng·h/mL) | 58.49 ± 25.76 | 59.52 ± 27.21 | 72.67 ± 36.74 | 76.0 ± 35.48 |
AUC0–∞ (ng·h/mL) | 68.05 ± 28.60 | 68.62 ± 30.60 | 88.50 ± 43.95 | 88.98 ± 38.33 |
Tmax (h) | 5.0 (0.50–24.0) | 5.0 (0.33–12.0) | 2.50 (0.50–6.0) | 2.50 (0.33–5.0) |
T1/2 (h) | 18.03 ± 6.52 | 19.38 ± 11.41 | 25.89 ± 12.01 | 26.62 ± 15.12 |
λz (h− 1) | 0.043 ± 0.015 | 0.048 ± 0.024 | 0.033 ± 0.018 | 0.033 ± 0.015 |
Ezetimibe glucuronic acid | ||||
Cmax (ng/mL) | 63.21 ± 47.14 | 68.55 ± 51.82 | 77.68 ± 37.25 | 79.22 ± 33.05 |
AUC0–t (ng·h/mL) | 575.78 ± 408.26 | 598.91 ± 441.88 | 409.29 ± 191.89 | 445.64 ± 196.37 |
AUC0–∞ (ng·h/mL) | 652.95 ± 407.06 | 690.65 ± 456.82 | 532.09 ± 214.84 | 550.38 ± 214.12 |
Tmax (h) | 1.75 (0.33–5.0) | 1.50 (0.33 ~ 5.0) | 2.50 (0.50–6.00) | 2.50 (0.50–5.0) |
T1/2 (h) | 20.36 ± 11.62 | 22.57 ± 21.67 | 31.05 ± 17.04 | 27.78 ± 13.71 |
λz (h− 1) | 0.049 ± 0.041 | 0.051 ± 0.036 | 0.028 ± 0.015 | 0.030 ± 0.012 |
Total ezetimibe | ||||
Cmax (ng/mL) | 65.73 ± 47.14 | 71.32 ± 51.98 | 83.38 ± 38.95 | 84.74 ± 34.62 |
AUC0–t (ng·h/mL) | 643.34 ± 400.77 | 668.49 ± 439.57 | 494.21 ± 208.65 | 536.69 ± 209.11 |
AUC0–∞ (ng·h/mL) | 706.36 ± 410.92 | 734.23 ± 468.26 | 573.74 ± 252.74 | 604.75 ± 247.13 |
Tmax (h) | 1.75 (0.33–5.0) | 1.25 (0.33–5.0) | 2.50 (0.50–5.0) | 2.50 (0.50–6.0) |
T1/2 (h) | 17.09 ± 13.22 | 17.35 ± 12.14 | 22.56 ± 12.68 | 19.80 ± 15.59 |
λz (h− 1) | 0.062 ± 0.042 | 0.061 ± 0.033 | 0.041 ± 0.022 | 0.052 ± 0.027 |